CNC vs LAB · P/E 8.4, rev $163.07B vs rev $174.4M
Centene Corp (CNC) versus Standard Biotools Inc (LAB) — a side-by-side from cached financials, not a winner call.
Centene Corp (CNC) is a healthcare plans company listed on US.
Standard Biotools Inc (LAB) is a medical devices company listed on NASDAQ.
Latest reported CNC revenue for 2024-12-31 was $163.07B. Net income was $3.29B. Revenue was up 5.9% from 2023-12-31 to 2024-12-31. CNC currently screens at market cap $28.19B and trailing P/E 8.4.
Latest reported LAB revenue for 2024-12-31 was $174.4M. Net income was -$138.9M. Revenue was up 64.0% from 2023-12-31 to 2024-12-31. LAB currently screens at market cap $317.1M.
CNC currently screens at market cap $28.19B and trailing P/E 8.4. LAB currently screens at market cap $317.1M.
Not investment advice. Open the CNC and LAB stock pages for the full models.
Not investment advice.